• CalciMedica's stock is up 5.7% to $0.76 following news of the U.S. Food and Drug Administration (FDA) aligning on the Phase 2b trial design for its lead candidate, Auxora™, in acute pancreatitis.
  • The FDA and CalciMedica agreed on new-onset severe respiratory failure as the primary endpoint for the Phase 2b trial.
  • This alignment is a crucial step towards a potential U.S. pivotal program for Auxora in acute pancreatitis, a serious disease with no approved therapies.